Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Department of Gynaecology and Obstetrics, Shenzhen Hospital of University of Hong Kong, Shenzhen, China.
Front Immunol. 2021 Nov 15;12:785717. doi: 10.3389/fimmu.2021.785717. eCollection 2021.
Intrauterine adhesion (IUA) is an endometrial fibrosis disease caused by repeated operations of the uterus and is a common cause of female infertility. In recent years, treatment using mesenchymal stem cells (MSCs) has been proposed by many researchers and is now widely used in clinics because of the low immunogenicity of MSCs. It is believed that allogeneic MSCs can be used to treat IUA because MSCs express only low levels of MHC class I molecules and no MHC class II or co-stimulatory molecules. However, many scholars still believe that the use of allogeneic MSCs to treat IUA may lead to immune rejection. Compared with allogeneic MSCs, autologous MSCs are safer, more ethical, and can better adapt to the body. Here, we review recently published articles on the immunomodulation of allogeneic and autologous MSCs in IUA therapy, with the aim of proving that the use of autologous MSCs can reduce the possibility of immune rejection in the treatment of IUAs.
宫腔粘连（IUA）是一种由子宫反复手术引起的子宫内膜纤维化疾病，是女性不孕的常见原因。近年来，间充质干细胞（MSCs）的治疗方法被许多研究人员提出，并因其 MSC 的低免疫原性而广泛应用于临床。人们认为同种异体 MSCs 可用于治疗 IUA，因为 MSC 仅表达低水平的 MHC Ⅰ类分子，而没有 MHC Ⅱ类或共刺激分子。然而，许多学者仍然认为使用同种异体 MSCs 治疗 IUA 可能会导致免疫排斥。与同种异体 MSCs 相比，自体 MSCs 更安全、更符合伦理，并且可以更好地适应机体。在这里，我们对同种异体和自体 MSCs 在 IUA 治疗中的免疫调节作用的已发表文章进行综述，旨在证明自体 MSCs 的使用可以降低治疗 IUAs 时免疫排斥的可能性。
